Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 05, 2020 16:01 ET | Source: Retrophin, Inc.

Retrophin Reports Third Quarter 2020 Financial Results

Pivotal DUPLEX Study of sparsentan in FSGS nears completion of enrollment; topline proteinuria data expected 1Q21 Pivotal PROTECT Study achieved enrollment of 280th patient with IgAN to enable...
July 16, 2020 16:30 ET | Source: Retrophin, Inc.

Retrophin to Report Second Quarter 2020 Financial Results

SAN DIEGO, July 16, 2020 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced it will report second quarter 2020 financial results on Thursday, July 30, 2020 after the close of the...
May 11, 2020 16:01 ET | Source: Retrophin, Inc.

Retrophin Reports First Quarter 2020 Financial Results

Enrollment continues in the pivotal DUPLEX and PROTECT studies of sparsentan DUPLEX Study of sparsentan in FSGS enrolled first 190 patients required for interim proteinuria analysis Net product...
October 30, 2019 16:01 ET | Source: Retrophin, Inc.

Retrophin Reports Third Quarter 2019 Financial Results

Enrollment on-track in pivotal Phase 3 clinical trials to support registration of sparsentan for patients with FSGS and IgAN Third quarter revenues rose nine percent to $44 million ...
February 26, 2019 16:01 ET | Source: Retrophin, Inc.

Retrophin Reports Fourth Quarter and Full Year 2018 Financial Results

Top-line results from pivotal Phase 3 FORT Study in PKAN expected in 3Q 2019 Two pivotal Phase 3 studies of sparsentan progressing on-track to enable potential first-in-class treatment for both FSGS...
February 12, 2019 16:30 ET | Source: Retrophin, Inc.

Retrophin to Report Fourth Quarter and Full Year 2018 Financial Results

SAN DIEGO, Feb. 12, 2019 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced it will report fourth quarter and full year 2018 financial results on Tuesday, February 26, 2019 after the...